Jeffrey Aronin, chairman and CEO of Paragon Biosciences, is a bioscience entrepreneur known for innovating, developing, and commercializing a record number of novel neurology medicines that improve the lives of seriously ill patients who have few or no treatments options. Paragon, which Aronin founded in 2017, is a global life science leader that creates, builds and funds innovative biology-based companies. It accelerates scientific breakthroughs to solve some of society’s most challenging medical problems. Paragon’s portfolio of high-growth companies includes Harmony Biosciences, Emalex Biosciences, and CiRC Biosciences. Aronin serves on corporate and civic boards including the Aspen Institute and the International Board of the Weizmann Institute of Science.
Previously
At the edge of innovation, government initiatives like the Advanced Research Projects Agency for Health (ARPA-H) are pursuing moonshots, venture capitalists are looking for im...
Sleep, perchance to dream—and to awaken restored, energetic, and prepared to meet the challenges of the day. The evolutionary gift of sleep lowers the risk of chronic disease,...